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INTRODUCTION
Cell lipid metabolism has been increasingly recognized to 
modulate the immune response in atherosclerosis and in 
autoimmune diseases.[1] It is well established that hyperlipi-
daemia, especially increased levels of low- density lipoprotein 
(LDL), is associated with an increased atherosclerosis risk 
whilst also contributing to the pathogenesis of autoimmune 
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Summary
Inflammation and immune dysfunction have been increasingly recognized as crucial 
mechanisms in atherogenesis. Modifications in cell lipid metabolism, plasma dyslipi-
daemia and particularly low high- density lipoprotein (HDL) levels occur both in ath-
erosclerosis and in autoimmune rheumatic diseases (which are strongly associated with 
an increased risk of atherosclerosis), suggesting the presence of a crucial link. HDL, the 
plasma lipoprotein responsible for reverse cholesterol transport, is known for its several 
protective effects in the context of atherosclerosis. Among these, HDL immunomodu-
latory effects are possibly the less understood. Through the efflux of cholesterol from 
plasma cell membranes with the consequent disruption of lipid rafts and the interaction 
with the cholesterol transporters present in the plasma membrane, HDL affects both the 
innate and adaptive immune responses. Animal and human studies have demonstrated a 
predominance of HDL anti- inflammatory effects, despite some pro- inflammatory actions 
having also been reported. The HDL role on the modulation of the immune response is 
further suggested by the detection of low levels together with a dysfunctional HDL in 
patients with autoimmune diseases. Here, we review the current knowledge of the im-
mune mechanisms of atherosclerosis and the modulatory effects HDL may have on them.
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diseases.[2] In fact, lipids are an important source of energy 
along with being membrane components indispensable for 
cell proliferation and migration, membrane expansion and 
other functions in the immune cells.[3]
High- density lipoprotein (HDL) is the plasma lipoprotein 
responsible for reverse cholesterol transport (RCT), which is 
associated with a protective role in atherosclerosis through 
reducing the lipid burden of atherosclerotic plaques.[4,5] In 
addition to its role in cholesterol efflux, other properties are 
attributed to HDL: inhibits LDL oxidation,[6] ameliorates 
endothelial function,[7] decreases monocyte adhesion to the 
endothelium and has anti- thrombotic and anti- inflammatory 
properties.[8,9] As such, HDL seems to be a crucial link be-
tween inflammation, immune activation and atherosclerosis. 
However, the consequences of the HDL- associated benefits 
have not been clear in clinical trials. This raises the question 
of HDL function or quality versus HDL quantity. HDL pro-
teomic studies revealed that variations in protein cargo can 
greatly influence HDL function. The study of the complex 
effects of HDL on the immune response in parallel with the 
increasing knowledge of the HDL constituents and their func-
tions may contribute to better understand the pathogenesis of 
atherosclerosis in inflammatory diseases and how this lipo-
protein relates to it. In order to put into context the different 
mechanisms involved, we reviewed the current information 
on HDL immunomodulatory effects and the atherosclerosis 
immune- associated pathways.
HDL, IMMUNE FUNCTION AND 
ATHEROSCLEROSIS
HDL structure and function
HDL is composed of a cholesterol core enriched with cho-
lesterol esters and triglycerides and a surface lipid bilayer 
containing free cholesterol, phospholipids and proteins. The 
HDL structure is modified during its maturation from small 
to large particles. Being the densest plasma lipoprotein, HDL 
is highly heterogeneous in size, charge and composition. The 
different proteins in HDL constitute more than half of its 
mass and render a high complexity to the HDL structure. The 
main HDL apolipoprotein is apolipoprotein A- I (ApoA- I), 
which makes up to approximately 70% of HDL protein. HDL 
particles also carry enzymes such as paraoxonase (PON), 
platelet- activating factor- acetyl- hydrolase (PAFAH), leci-
thin cholesterol acyltransferase (LCAT) and cholesteryl ester 
transfer protein (CETP).[10]
HDL mediation of cholesterol efflux is one of the main 
mechanisms by which HDL modulates the immune response. 
The lipid organization in the plasma membrane determines 
the constitution of micro- domains called lipid rafts, rich in 
glycosphingolipids and cholesterol, that are more ordered and 
less fluid than the surrounding membrane. Many functional 
proteins (including B- and T- cell receptors) are predomi-
nantly found in lipid rafts, which act as signalling platforms 
by colocalizing various signalling components.[11]
Cholesterol efflux to HDL occurs at higher rates through 
the adenosine triphosphate binding cassette transporters 
A1 (ABCA1) and G1 (ABCG1). The first complexes with 
ApoA- I to produce preβ- migrating HDL or very- small HDL 
particles, and the second promotes further lipidation to con-
stitute mature HDL particles. Cholesterol efflux occurs also 
through the scavenger receptor class B type I (SR- BI) and 
through aqueous diffusion.[12]
In macrophages, the cholesterol efflux to HDL mediated 
by ABCA1 and ABCG1 limits the cholesterol availability 
to constitute lipid rafts, which inhibits Toll- like receptors 
(TLRs) trafficking mediated by MyD88, an adaptor protein 
for all TLRs (except TLR3).[13] Activation of MyD88 after 
TLR ligation induces the factor nuclear kappa B (NF- kB) 
pathway. Mouse models deficient for ABCA1 and ABCG1 
were shown to accumulate cholesterol in peritoneal macro-
phages and have increased inflammatory responses to TLR 
agonists.[14] In T cells, the promotion of cholesterol efflux 
to HDL through ABCA1 and ABCG1 by liver X receptors 
(LXRs) is associated with a decrease in proliferation.[15] 
Mouse models of atherosclerosis lacking SR- BI showed an 
increased expression of pro- inflammatory cytokines, namely 
interleukin- 6 (IL- 6), tumour necrosis factor- α (TNF- α) and 
IL- 1- β.[16] At the cellular level, SR- BI regulates macro-
phage conversion to the inflammatory M1 form versus the 
anti- inflammatory M2 phenotype. SR- BI also regulates in-
flammation mediated by macrophages by reducing NF- kB, 
P38 and Janus kinase (JNK) signalling.[17] In humans, ge-
nomic analysis studies suggest that SR- BI decrease the risk 
of cardiovascular disease.[18]
Some of the HDL proteins are directly involved in the 
modulation of the immune response. These include ApoL- 
1, sphingosine- 1- phosphate (S1P), immunoglobulins and 
components of the complement system. ApoL- 1  has mi-
crobicidal activity through the formation of pores in the 
lysosomal membranes with the consequent lysis of trypano-
somes, which confers anti- parasitic properties to HDL.[19] 
S1P involved in several HDL is the main sphingolipid in 
HDL, and HDL is its principal transporter in plasma.[20] 
S1P binds to cells through its own cell surface receptors, 
contributing to immune cell trafficking and endothelial 
barrier function.[21] ApoM, a negative acute- phase pro-
tein, is the carrier of S1P in HDL. S1P is responsible for 
many of the HDL biological effects that are not related to 
reverse cholesterol transport.[22] These include immuno-
logical effects: inhibition of TNF- α- induced adhesion mol-
ecule expression in endothelial cells,[23] induction of long 
pentraxin 3 [24] and transforming growth factor- β (TGF- β) 
in endothelial cells,[25] inhibition of TLR2 activation in 
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macrophages,[26] reduction in pro- inflammatory and in-
crease in anti- inflammatory cytokine production by den-
dritic cells (DCs),[27] migration of T lymphocytes from 
lymphoid organs [28] and control of T- cell lineage deter-
mination.[29] Acute- phase proteins, such as serum amy-
loid A (SAA), are also abundant in HDL, reinforcing its 
role in the immune response.[30]
HDL effects on immune modulation can be relevant not 
only to the pathogenesis of atherosclerosis but also to other 
inflammatory conditions. Experimental studies showed that 
low HDL increases the risk of infection. In humans, low 
HDL levels inversely correlate with the severity of sepsis.
[31] However, very high HDL levels were also associated 
with higher risk of infection in a population study,[32] which 
is still puzzling. In population cohorts, low HDL levels are 
associated with increased risk of infection- related hospital-
izations,[33] particularly with bacterial infections. It is at-
tributed to the capacity of HDL to decrease the pathogenicity 
of bacteria by limiting endotoxin toxicity, as HDL is a che-
lator of lipopolysaccharide (LPS) from Gram- negative and 
lipoteichoic acid (LTA) from Gram- positive bacteria. The 
clearance of HDL- LPS complex in mediated by SR- BI.[34] 
HDL also limits the activation of the innate immune system 
by the pathogen and modulates the adaptive response.[35] In 
addition, HDL provides cholesterol for glucocorticoid syn-
thesis after interaction with SR- BI,[36] which can influence 
the outcome in the context of sepsis.
In autoimmune rheumatic diseases, plasma lipoprotein 
profiles are commonly altered, with several studies report-
ing a decrease in HDL plasma concentrations.[37] Low HDL 
levels are associated with an increased risk of autoimmune 
disease, both in animal and in human studies. LDLR- /- apoA- 
I- /- mice showed enlarged peripheral lymph nodes (LNs) 
and spleens, compared with LDLR- /- mice, and increased 
proliferation of LN cells that showed an autoimmune phe-
notype.[38,39] SR- BI- deficient mice developed a systemic 
autoimmune disorder,[40] which is probably related to the 
consequent modifications in HDL, which is less capable of in-
hibiting lymphocyte proliferation.[41,42] In the Copenhagen 
General Population Study and the Copenhagen City Heart 
Study, a low HDL level was associated with an increased risk 
of autoimmune disease. However, in the Copenhagen City 
Heart Study very high HDL levels were also associated with 
autoimmune diseases,[32] suggesting that function and not 
only quantity could be at play.
Low HDL levels are also one of the factors contributing to 
the high prevalence of atherosclerotic plaques and cardiovas-
cular disease among individuals with autoimmune rheumatic 
diseases.[43] However, mendelian randomization genetic 
studies suggest that HDL functionality (mainly related to 
cholesterol efflux capacity) may be more important than 
HDL plasma concentration in the pathogenesis of cardiovas-
cular diseases.[44] Several studies in autoimmune rheumatic 
diseases demonstrated that HDL dysfunction is frequently 
present.[45- 47] In rheumatoid arthritis, HDL- mediated cho-
lesterol efflux is impaired in patients with active disease. In 
systemic lupus erythematosus, the cholesterol efflux medi-
ated by ABCA1 and ABCG1 is compromised despite not cor-
relating with disease activity.[46] Additionally, HDL from 
patients with SLE and rheumatoid arthritis (RA) was shown 
to be pro- inflammatory and associated with increased levels 
of oxidized LDL (oxLDL).[48] HDL from patients with an-
kylosing spondylitis and psoriasis also showed to have sev-
eral functional modifications.[49,50] Interestingly, the HDL 
functional properties are usually independent from its serum 
levels and so the role of HDL dysfunction in the pathogene-
sis of autoimmune rheumatic diseases is still not completely 
understood. There are many factors leading to modifications 
in HDL function in the context of inflammation. HDL can 
be modified by the binding of acute- phase proteins, comple-
ment factors and other inflammatory proteins.[48,51] The 
humoral response against HDL components, associated with 
increased cardiovascular risk, may also be an important cause 
of HDL dysfunction.[52,53] In inflammatory conditions, 
HDL loses antioxidant capacity consequent to a decreased 
content of PON1 [54] and increased levels of PAFAH.[55,56] 
This impairment of the antioxidant capacity is associated 
with an increase in oxLDL levels. A decrease in ApoM also 
occurs, thus affecting the function of S1P.[57] As a result, 
dysfunctional HDL loses anti- inflammatory properties and 
can promote inflammation.[58]
The effects of HDL on inflammation and 
atherosclerosis
The cholesterol content of plasma membranes is crucial to 
immune cell function and can be highly influenced by the 
presence of HDL. Intracellular cholesterol, in the form of ox-
ysterols, is also relevant as it binds to the LXRs (LXRα and 
LXRβ) and participates in the regulation of various pathways 
linked to inflammation and immune response.[15] LXRs 
also promote the expression of the cholesterol transporters 
ABCA1 and ABCG1.[59]
Lipid metabolism can affect the innate immune response, 
mainly through modulation of TLR- dependent macrophage 
and adaptive immune responses, namely T- cell proliferation 
and differentiation into Th17 and Treg cells.[60] The increase 
in lipid rafts resultant from cholesterol accumulation in T 
cells predisposes to higher inflammatory reactivity through 
the facilitation of TCR contact with costimulatory receptors 
in lipid rafts.[61] Membrane cholesterol also influences the 
immune synapse formation through variations in lipid raft 
abundance and membrane fluidity.[62] In B cells, lipid rafts 
are thought to promote BCR signalling [63] and membrane 
cholesterol influences BCR endocytosis.[64]
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The increasing number of studies on the HDL immu-
nomodulatory effects shows a wide variety of mechanisms 
involved. However, the use of different methodologies adds 
complexity to the analysis of an interpretation of these stud-
ies. The available evidence from animal and human studies, 
frequently contradictory, will be reviewed separately and is 
summarized in Figure 1.
Immune effects of HDL in animal studies
Mouse studies have shown several anti- inflammatory ef-
fects of HDL, mainly on endothelial cells and cells of the 
innate immune system. Mice overexpressing ApoA- I had 
lower NF- kB signalling (IL- 6, TNF- α, monocyte chemo- 
attractant protein 1 – MCP- 1) in endothelial cells, in re-
sponse to palmitate.[65] However, conflicting results arose 
from other studies showing no influence of HDL in NF- 
kB in mouse macrophages [66] or activation of the protein 
kinase C (PKC)- NK- kB/signal transducer and activator 1 
(STAT1) – interferon regulatory factor 1 (IRF1) axis due to 
cholesterol depletion in the presence of HDL in murine and 
human primary macrophages.[67] The anti- inflammatory ef-
fects of HDL on mouse macrophages seem to be related to 
a decrease in lipid rafts consequent to the cholesterol efflux 
from cells, a reduction in reactive oxygen species generation 
through its antioxidant properties and an inhibition of TLR4 
and nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase 2 translocation into the lipid rafts.[68] Cholesterol 
accumulation in mouse myeloid cells activates the NOD- like, 
LRR- like and pyrin domain- containing protein 3 (NLRP3) 
inflammasome,[69] which is linked to the HDL- induced re-
duction in polymorphonuclear (PMN) leucocyte infiltration 
in the atherosclerotic plaque.[70,71] In fact, mice lacking the 
cholesterol transporters ABCA1 and ABCG1 showed leu-
cocytosis and a myeloproliferative disorder, which resolved 
after bone marrow transplantation into transgenic mice with 
high levels of HDL,[72] demonstrating that cholesterol 
F I G U R E  1  HDL immune effects mediated by cholesterol efflux. The different cholesterol efflux pathways may have diverse effects on 
immune response. However, in many studies the specific involved pathway was not determined. Lipid raft disruption in consequence of cholesterol 
efflux is related to many of the HDL effects on immune response. DC: dendritic cell. TLR: Toll- like receptor. NLRP3: nucleotide binding domain 
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transporters and HDL suppress haematopoietic stem cell pro-
liferation. ABCA1 has additional anti- inflammatory effects 
(that rely on ApoA- I ligation but are independent of choles-
terol efflux) through the activation of the JAK2/STAT3 path-
way, which suppresses the production of pro- inflammatory 
cytokines.[73] HDL was also reported to promote activating 
transcription factor 3 (ATF3)- mediated anti- inflammatory 
effects at supra- physiological concentrations in mouse mac-
rophages,[66] but this effect was not observed when treating 
cells with HDL at physiological concentrations nor in human 
macrophages.[74] HDL also exerts pro- inflammatory effects 
in mouse macrophages. Fotakis et al verified that the infu-
sion of reconstituted HDL into atherosclerotic mice induces 
anti- inflammatory effects related to reduced TLR4 levels 
and reduced interferon (IFN) receptor signalling, and late 
pro- inflammatory effects due to a modified endoplasmic re-
ticulum stress response in the context of extreme cholesterol 
depletion.[75] However, in lesion macrophages the anti- 
inflammatory effects predominate.
With respect to the adaptive immune response, the ca-
pacity of moue antigen- presenting cells to activate T cells 
is reduced by HDL and ApoA- I through cholesterol efflux 
and lipid raft disruption [76] and by inhibiting the production 
of some inflammatory cytokines (TNF- α, IL- 1β, IL- 6, IL- 8, 
MIP- 1 and MIP- 1β).[77] Increased levels of plasma mem-
brane cholesterol have been reported to promote the inflam-
matory T helper response.[78] Mouse splenocytes stimulated 
with TCR or BCR ligands showed a decreased T- and B- cell 
proliferation rate in the presence of HDL.[40] In another 
study, ApoA- I was shown to decrease lymph node immune 
cells and increase Tregs in LDLr - /- , apoA- I - /- mice fed with 
an atherogenic diet.[39]
Immune effects of HDL in human studies
Studies with human cells showed that HDL and ApoA- I re-
duce PMN leucocyte adherence to endothelial cells in vitro, 
through blocking LPS activity and modifying CD11b/CD18 
on PMN,[79] and also protect against the neutrophil respira-
tory burst.[80,81] The ApoA- I inhibitory effect on CD11b 
of activated neutrophils is mediated through ABCA1, and 
the HDL effects are mediated by SR- BI. SR- BI assumes a 
relevant role in cholesterol efflux from macrophages as it 
mediates anti- inflammatory signalling in macrophages and 
endothelial cells [82] and mediates the efferocytosis of ap-
optotic cells.[83] Endothelial cell SR- BI mediates the uptake 
and transcytosis of HDL in lymphatic vessels to effectively 
remove cholesterol from the peripheral tissue, thereby rais-
ing the possibility that lymphatic SR- BI may also reduce the 
foam cell formation in atherosclerotic lesions.[84]
HDL- and ApoA- I- mediated cholesterol efflux results 
in the decrease in lipid raft abundance. In macrophages, the 
reduction in available lipid rafts correlates with the decrease 
in CD11b activation. These results are corroborated by the 
observation that the infusion of reconstituted HDL in patients 
with peripheral vascular disease attenuates neutrophil activa-
tion.[85] There is also a negative correlation between HDL 
and leucocyte levels in patients with coronary artery disease.
[86] However, HDL from healthy young individuals demon-
strated to increase the proliferation of stimulated T cells.[87] 
In fact, the effects of HDL on lymphocyte proliferation are 
not clarified, with conflicting results arising from different 
studies. It is very likely that variations in HDL function, con-
centration and lipid composition can exert different effects. 
Apart from the effects of HDL on immune cell proliferation, 
other aspects of the immune response have also been stud-
ied in human cells and patients. HDL and ApoA- I inhibit the 
expression of inflammation markers, increase IL- 10 produc-
tion and promote spreading in primary human monocytes.
[88,89] In human macrophages infected with mycobacteria, 
HDL reduced TNF- α production through the downregula-
tion of TLR2 and the consequent suppression of the NF- kB, 
p38 and JNK mitogen- activated protein kinase pathways. In 
these macrophages, HDL also reduced the production of IL- 
6, IFN- γ and IL- 4 in a dose- dependent manner and increased 
the production of IL- 10.[74] ApoA- I inhibited the soluble 
CD40L- stimulated activation of NF- kB in human THP- 1 
macrophage- derived foam cells, which seems to depend on 
the interaction with ABCA1.[90] HDL and ApoA- I also de-
crease the production of inflammatory cytokines (TNF- α, 
IL- 1β) by human T- cell lines.[91] The interaction between 
antigen- presenting cells and T cells in human peripheral 
blood mononuclear cells (PBMCs) was shown to be affected 
by ApoA- I as it may decrease DC activation and differenti-
ation and reduce the production of IFN- γ by T cells in re-
sponse to DC interaction.[92] HDL also affects the human 
DC ability to induce Th1 response upon TLR stimulation.
[93] Furthermore, HDL binds stimulated T lymphocytes, 
through ApoA- I interaction with cell surface factors, and in-
hibits the contact- mediated activation of monocytes with a 
consequent lower production of TNF- α and IL- 1β.[91]
Regarding the T- cell repertoire, HDL seems to play an es-
sential role in Treg modulation. Tregs differ from other lym-
phocytes in its metabolic requirements, as they rely mostly on 
lipids as the source of energy to survive.[94,95] Treg counts 
increase in the presence of HDL at physiological concentra-
tions, in a dose- dependent manner, with a decrease in the 
percentage of apoptotic Treg, suggesting that HDL promotes 
the survival of human Treg. This effect was not seen in other 
T- cell populations.[96] In a study that showed an increase in 
the frequency and absolute numbers of Treg in healthy indi-
viduals taking statins, the increase in HDL levels showed a 
positive correlation with the Treg counts.[97]
In summary, both HDL and its main apolipoprotein 
ApoA- I decrease inflammation mediated by monocytes/
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macrophages and neutrophils. The existent studies point TLR 
signalling and NF- kB pathways as the principal targets in the 
innate immune system. In the adaptive immune system, HDL 
affects T- cell proliferation, increases the prevalence of Treg 
and modulates cytokine production. Overall, the disruption 
of lipid rafts seems to be crucial to the modulation of the im-
mune response by HDL, bearing in mind that HDL can also 
exert pro- inflammatory effects under specific circumstances.
IMMUNE MECHANISMS OF 
ATHEROSCLEROSIS
Atherosclerosis, a leading cause of mortality worldwide, is 
a chronic inflammatory disease of large- and medium- sized 
arteries with an important immunological component.[98] 
For many years, it was believed that atherosclerosis was sim-
ply due to passive accumulation of cholesterol in the vessel 
wall. In fact, endothelial dysfunction and inflammation are 
early pro- atherogenic processes and it is becoming increas-
ingly clear that innate and adaptive immune responses play 
important roles in atherogenesis. The atherosclerotic plaque 
is characterized by an accumulation of lipids in the artery 
wall, together with infiltration of immune cells and the for-
mation of a fibrous cap by vascular smooth muscle cells. 
However, the interaction between lipid mediators and the 
immune system in the context of atherosclerosis is not com-
pletely understood.
One of the most well- known interactions between lipo-
proteins and the immune response is the activation of the in-
nate immunity through the detection of danger signals, such 
as oxLDL, by sensor proteins in the cytoplasm of innate im-
mune cells.[99] These sensor proteins are constituents of in-
flammasomes that are responsible for a rapid inflammatory 
response through the cleavage of IL- 1β and IL- 18 into the 
pro- inflammatory active forms. NLRP3 is the inflammasome 
associated with chronic inflammation in atherosclerosis [100] 
and is also activated by the TLR4 downstream signalling.
[101] In a normal artery wall, resident DCs promote toleriza-
tion to antigen by silencing T cells. However, danger signals 
may activate DCs, leading to a switch from tolerance to the 
activation of adaptive immunity. In fact, DCs are clustered in 
arterial branch points, where they colocalize with T cells and 
macrophages.[102] Macrophages assume a relevant role in the 
development of the atherosclerotic lesions through the uptake 
of oxLDL, mainly by SRs, and then transforming themselves 
into foam cells.[103] OxLDL also binds to TLR2 and TLR4, 
activating the inflammasome and inducing the excretion of 
pro- inflammatory cytokines.[104] During inflammation, 
oxLDL can be internalized by macrophages independently 
of SRs, and macrophages can polarize to a M1 phenotype, 
with the suppression of the lipid sensors LXR and peroxi-
some proliferator- activated receptor (PPAR).[105] These 
mechanisms perpetuate the inflammatory response in the ves-
sel wall, with the consequent activation of a type 1 T helper 
(Th1) response,[106] which often become chronic.[107]
In the atherosclerotic lesions of mouse models, there is a 
macrophage/T- cell ratio of approximately 4:1 to 10:1.[108] 
Most T cells in those atherosclerotic plaques are CD4+, and 
the remaining are CD8+ T cells. The CD4+ T cells predom-
inantly have a Th1 profile that activate macrophages and in-
crease pro- inflammatory cytokines, such as IFN- γ, TNF- α 
and IL- 2. IFN- γ, the main pro- inflammatory cytokine in-
volved, increases the expression of other inflammatory cyto-
kines, such as IL- 1.[109] Th2, Th17, regulatory T cells (Treg) 
and natural killer (NK) T cells are also present, but whilst the 
Th1 profile is associated with atherosclerosis progression, 
the role of the other T- cell subsets is less clear. In fact, the 
role of Th2 cells is controversial [110- 112] and the Th17 im-
pact seems to be context- dependent: if IL- 17 expression is 
accompanied by high levels of IFN- γ, it is atherogenic, but in 
the presence of IL- 10, it is protective.[113]
Tregs are a subset of CD4+ T cells that protect against ath-
erogenesis through the inhibition of pro- inflammatory T cells 
[114] and the suppression of macrophages and endothelial 
cell activation. The principal inhibitory cytokines secreted by 
Treg are IL- 10 and TGF- β.[115] Hypercholesterolaemia was 
shown to impair Treg, but not the effector T- cell accumulation 
in lesions, thus contributing to the decrease in Treg:Th1 cell 
ratios in atherosclerotic lesions.[116,117] A negative correla-
tion between Treg and Th17 cells was also found in patients 
with unstable carotid artery lesions.[118] Additionally, Tregs 
from patients with acute coronary syndrome were shown to 
have a reduced suppressive function.[119]
The role of B cells in atherosclerosis is related to both the 
humoral and the modulation of cellular responses with anti- 
atherogenic and pro- atherogenic effects. B1 cells produce 
naturally occurring IgM antibodies directed to oxidation- 
specific epitopes that neutralize them and limit endothelial 
activation and foam cell formation. In contrast, B2 cells 
produce IgG antibodies that are pro- atherogenic through the 
formation of immune complexes (e.g. with oxLDL) and pro-
motion of macrophage inflammatory responses.[120] IgE an-
tibodies are also pro- atherogenic by stimulating macrophages 
and mast cells.[121] The role of IgA in atherosclerosis is less 
understood, but it was reported to have a positive correla-
tion between IgA antibodies and cardiovascular disease.[122] 
Additionally, B cells can produce pro- atherogenic and anti- 
atherogenic cytokines.[123,124] Studies on B- cell- mediated 
regulation of immune responses showed that B- cell depletion 
decreases T- cell activation. However, blocking the B- cell- 
activating factor (BAFF) seems to worsen atherosclerosis in 
mouse models, as the ligation to its main receptor (BAFFR) 
leads to B2 cell differentiation and increases IgG levels in 
mice. Interestingly, the ligation of BAFF to its alternative 
receptor (TACI) decreases the TLR9- interferon regulatory 
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factor responses in macrophages, which explains its anti- 
atherogenic net effect.[125] Indeed, the pharmacologic CD20 
blockade showed to be atheroprotective, partly because of a 
selective depletion of IgG- producing B cells with an incom-
plete depletion of IgM- producing B cells and partly through 
an increase in BAFF levels.[126]
The reported mechanisms were observed mainly in stud-
ies using mouse models. In humans, cells in atherosclerotic 
plaques also express TLR family members. However, the role 
of TLRs in the pathogenesis of atherosclerosis seems to be 
different among human studies: in one study, loss- of- function 
mutations in the TLR4 gene decreased cardiovascular disease, 
but subsequent studies did not show a protective effect of a 
hyporesponsive TLR4 allele.[127] The role of the different 
immune cells in atherosclerosis may also vary between mice 
and humans. In the human atherosclerotic plaque, polymor-
phonuclear leucocytes are fewer than in mice; DCs increase 
in atherosclerotic lesions, both in mice and in humans [128]; 
T cells in the human atherosclerotic plaque predominantly ex-
hibit a Th1 cell- associated cytokine secretion pattern, although 
with less degree of polarization than in mice.[129] The role 
of deregulated immune response in the pathogenesis of human 
atherosclerosis is also evident in inflammatory and autoim-
mune diseases in which atherogenesis is accelerated. Several 
infections have been implicated as triggers to inflammation in 
the pathogenesis of atherosclerosis. Some of the implicated in-
fectious agents are Epstein– Barr virus, herpes simplex virus, 
cytomegalovirus, Helicobacter pylori and Chlamydia pneumo-
niae.[130] Chronic infectious diseases, such as periodontitis 
or bronchitis, also accelerate atherosclerosis. In patients with 
autoimmune rheumatic diseases, accelerated atherosclerosis 
and cardiovascular events are an important cause of morbidity 
and mortality. The autoimmune rheumatic diseases most com-
monly associated with atherosclerosis progression are rheu-
matoid arthritis, SLE and Sjogren's syndrome, although many 
other diseases have also demonstrated an increase in athero-
sclerosis. Antibodies against oxLDL were reported in higher 
titres in the serum of patients with autoimmune rheumatic dis-
eases, in comparison with controls.[131] Other autoantibodies 
have also been implicated in the pathogenesis of atherosclero-
sis in the context of autoimmune rheumatic diseases, such as 
anti- cardiolipin and ant- 2GPI in the context of SLE.
Chronic inflammation, with immune cell infiltration of 
the vessel, is one of the main contributors to atherosclero-
sis. In addition to cellular immunity, humoral immunity with 
antibodies directed to HDL epitopes is also implicated in the 
pathogenesis of atherosclerosis.
CONCLUSIONS
HDL effects in the regulation of the immune response are 
complex and probably context- dependent, protecting from 
excessive inflammation without compromising the immune 
response to pathogens. HDL functionality is thus far beyond 
reverse cholesterol transport, with an effect in the immune 
system that is closely related to the lipid metabolism ongo-
ing in the immune cells. The knowledge of atherosclerosis- 
associated immune mechanisms in parallel with the 
knowledge of lipid metabolism and the HDL impact on the 
immune response may show a different perspective into 
the underlying pathways present in this complex disease. 
Among the studied HDL immunomodulatory effects, the de-
crease in monocytes/macrophages and neutrophil activation, 
modulation of cytokine production and promotion of Treg 
population counteract some of the immune mechanisms 
thought to be implicated in atherosclerosis. The effects of 
HDL on the Treg population also suggest a role for HDL 
in the regulation of immune tolerance mechanisms, which 
deserve to be investigated in the context of autoimmune dis-
eases. This will hopefully give more clues towards improv-
ing the treatment of both the atherosclerotic cardiovascular 
disease and the autoimmune diseases with an increased risk 
of atherosclerosis.
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